Q32 Bio Inc. 8-K

What Happened
Q32 Bio Inc. (QTTB) filed an 8-K (Item 5.02) on December 19, 2025, reporting that Board Chair Mark Iwicki has withdrawn his previously announced resignation. Mr. Iwicki had notified the Company he intended to resign effective December 31, 2025, to reduce the number of boards he serves on and focus on his CEO role at Inhibikase Therapeutics, Inc. On December 17, 2025, with the full support of the Board, he rescinded that resignation effective immediately and will remain Chair of the Board and Chair of the Compensation Committee, and will continue as a member of the Audit Committee.

Key Details

• Filing: Form 8-K filed by Q32 Bio Inc. on December 19, 2025 (Item 5.02).
• Resignation timeline: Initially intended to resign effective December 31, 2025; withdrawal effective December 17, 2025.
• Roles preserved: Mr. Iwicki will remain Chair of the Board and Chair of the Compensation Committee, and stay on the Audit Committee.
• Stated reason: He had planned to reduce his board commitments to focus on his CEO role at Inhibikase; after reducing other board commitments, he withdrew his resignation with Board support.

Why It Matters
This update signals continuity in Q32 Bio’s board leadership and governance: the Chair and Compensation Committee chair positions remain unchanged, which can reduce near-term governance uncertainty for investors. Because this is a withdrawal of a planned departure (not a new appointment or unexpected exit), there is no immediate change to board composition or committees that would require further disclosure beyond the 8-K.